The AMPK modulator metformin as adjunct to methotrexate in patients with rheumatoid arthritis: A proof-of-concept, randomized, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

The AMPK modulator metformin as adjunct to methotrexate in patients with rheumatoid arthritis: A proof-of-concept, randomized, double-blind, placebo-controlled trial

Published:2021-06 Issue: Volume:95 Page:107575
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Abdallah Mahmoud S.^ORCID,Alarfaj Sumaiah J.,Saif Dalia S.,EL-Naggar Mostafa E.,Elsokary Mohamed A.,Elsawah Hozaifa K.^ORCID,Abdelsattar Zaki Shimaa,Wahsh Engy A.,Abo Mansour Hend E.,Mosalam Esraa M.

Publisher

Elsevier BV

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference58 articles.

1. A clinical update and global economic burden of rheumatoid arthritis;Fazal;Endocr. Metab. Immune Disord. Drug. Targets,2018

2. Genes, environment and immunity in the development of rheumatoid arthritis;Klareskog;Curr. Opin. Immunol.,2006

3. Current therapeutic options in the treatment of rheumatoid arthritis;Köhler;J. Clin. Med.,2019

4. Treatment of rheumatoid arthritis: state of the art 2009;van Vollenhoven;Nat. Rev. Rheumatol.,2009

5. The role of T helper type 17 cells in inflammatory arthritis;Sarkar;Clin. Exp. Immunol.,2010

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Shikonin suppresses rheumatoid arthritis by inducing apoptosis and autophagy via modulation of the AMPK/mTOR/ULK-1 signaling pathway;Phytomedicine;2024-06

2. Glucagon-like peptide-1 receptor agonists: Prospects for use in rheumatology;Rheumatology Science and Practice;2024-04-28

3. AMPK, a key molecule regulating aging-related myocardial ischemia-reperfusion injury;Molecular Biology Reports;2024-02-01

4. Efficacy of montelukast as an adjuvant therapy in rheumatoid arthritis patients: A randomized controlled study;International Immunopharmacology;2023-11

5. Regulatory T Cell-Targeted Immunomodulatory Therapy for Long-Term Clinical Improvement of Atopic Dermatitis: Hypotheses and Perspectives;Life;2023-08-01